A. Adderkin
University of Sydney
3 Papers
1 Citations
A. Adderkin is an academic researcher from University of Sydney. The author has contributed to research in topics: Internal medicine & Pembrolizumab. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
850 Interim results for phase 1b dose expansion of MTL-CEBPA in combination with pembrolizumab in patients with advanced solid tumour malignancies
Ruth Plummer,Mikael H. Sodergren,B. Ryan,Ilian Tachkov,Vikash Reebye,Tim Meyer,David J. Pinato,Debashis Sarker,Bristi Basu,Sarah P. Blagden,Natalie Cook,Jeff Evans,Jeffrey Yachnin,Cheng E. Chee,Daneng Li,Anthony B. El-Khoueiry,Maria Diab,Kai-Wen Huang,Antonio D'Alessio,Claudia Angela Maria Fulgenzi,Marcus Smith Noel,Bridget P. Keenan,Devalingam Mahalingam,Nina Raulf,Rose Hogson,Choon Ping Tan,Joanna Nicholls,A. Adderkin,Julia Vassiliadou,Robert H. Habib,John J. Rossi,Nagy A. Habib +31 more
- 01 Nov 2022
TL;DR: In this paper , the authors reported dose escalation data for MTL-CEBPA in combination with ICI from TIMEPOINT, an ongoing multi-centre phase 1/1b study (NCT-04105335).
Abstract LB192: MTL-CEBPA in combination with pembrolizumab converts an immune desert to an inflamed TME in solid tumors resistant to checkpoint blockade
Ruth Plummer,Mikael H. Sodergren,B. Ryan,Ilian Tchakov,Nina Raulf,C. Tan,Joanna Nicholls,A. Adderkin,Vikash Reebye,Tim Meyer,David J. Pinato,Debashis Sarker,Bristi Basu,Sarah P. Blagden,Natalie Cook,Jeff Evans,Jeffrey Yachnin,Cheng E. Chee,Daniel Li,Anthony B. El-Khoueiry,Maria Diab,Kai-Wen Huang,Marcus Smith Noel,Bridget P. Keenan,Devalingam Mahalingam,Denis Arnaud,Aurélie Auguste,J.H. Storkholm,Iain A. McNeish,Robert H. Habib,John J. Rossi,Nagy A. Habib +31 more
TL;DR: Plummer et al. as discussed by the authors reported the findings from a biomarker pharmacodynamic analysis of paired baseline and cycle 2 tumor sample biopsies in 23 patients from the TIMEPOINT trial.
Study rationale and design of ADVANCE: Action in diabetes and vascular disease - Preterax and diamicron MR controlled evaluation
John Chalmers,M. Cooper,E. Ferrannini,Paul Glasziou,De Grobbee,P. Hamet,Stephen B. Harrap,Liusheng Liu,Stephen MacMahon,G. Mancia,Michel Marre,D. Matthews,C. Mogensen,Bruce Neal,C. Yu Pan,N. Poulter,Anthony Rodgers,B. Williams,Mark Woodward,Rory Collins,Peter Sandercock,P. Sleight,Rury R. Holman,Greg Fulcher,Carol A. Pollock,David S. Celermajer,John D.G. Watson,B. Harrisberg,R. Currie,Seham Girgis,K. Jayne,Helen Monaghan,Anushka Patel,A. Richens,B. Gray,A. Milne,A. Adderkin,A. Bak,S. Flett,D. De Guise,E. Jetses,J. Reid,Ronald P. Stolk,W. Wang,F. Williams,X. Zou +45 more
TL;DR: The ADVANCE trial as discussed by the authors was designed to provide reliable evidence on the balance of benefits and risks conferred by blood pressure lowering therapy and intensive glucose control therapy in high-risk diabetic patients, regardless of initial blood pressure or glucose concentrations.